Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Friday morning. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $0.19 on Friday. The business has a fifty day simple moving average of $0.16 and a 200-day simple moving average of $1.02. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $22.14. The company has a market cap of $35.45 million, a P/E ratio of 0.00 and a beta of 2.06. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Equities research analysts forecast that Tonix Pharmaceuticals will post -18 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.